SCHEMBL177526

SCHEMBL177526

OB(O)c1ccc(C(F)(F)F)c(Cl)c1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TTR P02766 3/20 0.50
MGLL Q99685 2/20 0.47
ENPP2 Q13822 2/20 0.41
KMO O15229 2/20 0.41
NOTUM Q6P988 3/20 0.38
ORAI1 Q96D31 1/20 0.38
ORAI2 Q96SN7 1/20 0.38
ORAI3 Q9BRQ5 1/20 0.38
TRPV6 Q9H1D0 1/20 0.38
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
HTR3E A5X5Y0 1/20 0.36
HTR3B O95264 1/20 0.36
HTR3A P46098 1/20 0.36
HTR3D Q70Z44 1/20 0.36
HTR3C Q8WXA8 1/20 0.36
KDR P35968 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL177582 0.84 HTR3E (0.47) TTRMGLLENPP2NOTUMHTR3E
SCHEMBL29465748 0.84 HTR3E (0.47) TTRMGLLENPP2NOTUMHTR3E
SCHEMBL257854 0.81 CA1 (0.47) MGLLENPP2KMOCA1CA2
SCHEMBL3789433 0.81 MGLL (0.52) TTRMGLLENPP2ORAI1ORAI2
SCHEMBL29700447 0.81 MGLL (0.52) TTRMGLLENPP2ORAI1ORAI2
SCHEMBL24425082 0.80 TTR (0.50) TTRENPP2CA1CA2
SCHEMBL29956269 0.78 MGLL (0.48) TTRMGLLENPP2ORAI1ORAI2
SCHEMBL1231962 0.78 KIF11 (0.48) MGLLORAI1ORAI2ORAI3TRPV6
SCHEMBL3787045 0.76 MGLL (0.47) TTRMGLLENPP2ORAI1ORAI2
SCHEMBL20475565 0.76 MGLL (0.47) TTRMGLLENPP2ORAI1ORAI2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7820108-B2 Marker detection method and apparatus to monitor drug compliance UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2010-10-26 US claimed
US-20040081587-A1 Marker detection method and apparatus to monitor drug compliance MELKER RICHARD J (US) 2004-04-29 US claimed
EP-4719385-A2 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINES AS ANTI-INFECTIOUS AGENTS University of Vermont and State Agricultural College (US) 2026-04-08 EP disclosed
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON INC (US) 2026-03-12 US disclosed
US-12509474-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2025-12-30 US disclosed
US-20250361236-A9 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2025-11-27 US disclosed
WO-2025215450-A1 THIAZOLE COMPOUNDS AS SODIUM CHANNEL BLOCKERS SK BIOPHARMACEUTICALS CO., LTD. (KR) 2025-10-16 WO disclosed
US-20250257064-A1 TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2025-08-14 US disclosed
US-12371431-B2 Trifluoromethyl-substituted sulfonamide as BCL-2-selective inhibitor CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2025-07-29 US disclosed
CN-119874668-A Main protease regulator and application thereof 北京昌平实验室 2025-04-25 CN disclosed
US-20250074889-A1 Novel Aminobenzene Derivative Having Cancer Cell Growth Inhibitory Effect, and Preventive or Therapeutic Pharmaceutical Composition Containing Same as Active Ingredient DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2025-03-06 US disclosed
US-20080015223-A1 Pyrazole Derivatives as Modulators of the 5-Ht2a Serotonin Receptor Useful for the Treatment of Disorders Related Thereto ARENA PHARMACEUTICALS, INC. (US) 2008-01-17 US disclosed
EP-1874753-A2 COMPOUNDS, COMPOSITIONS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 2008-01-09 EP disclosed
US-20070203210-A1 Thiazolyl-benzimidazoles BOYLAN JOHN FREDERICK 2007-08-30 US disclosed
WO-2006113432-A2 COMPOUNDS, COMPOSITIONS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 2006-10-26 WO disclosed
US-20060223852-A1 Pyrazoles GILLESPIE PAUL 2006-10-05 US disclosed
WO-2006060762-A2 PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2006-06-08 WO disclosed
WO-2006012577-A2 QUINAZOLINONE DERIVATIVES USEFUL FOR THE REGULATION OF GLUCOSE HOMEOSTASIS AND FOOD INTAKE BAYER PHARMACEUTICALS CORPORATION (US) 2006-02-02 WO disclosed
US-20040166063-A1 marking a pharmaceutical product, container or pharmaceutical packaging system with a scent to establish the identity and/or source of the pharmaceutical PURDUE PHARMA L.P. 2004-08-26 US disclosed
US-20040081587-A1 Marker detection method and apparatus to monitor drug compliance MELKER RICHARD J (US) 2004-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015223-A1 Pyrazole Derivatives as Modulators of the 5-Ht2a Serotonin Receptor Useful for the Treatment of Disorders Related Thereto HTR5A, HTR2A, HTR3A TTR 598/4885MGLL 1467/4885ENPP2 487/4885
US-20070203210-A1 Thiazolyl-benzimidazoles CYP3A7, CYP2C19, CYP3A5 TTR 144/4885MGLL 2572/4885ENPP2 4807/4885
US-12371431-B2 Trifluoromethyl-substituted sulfonamide as BCL-2-selective inhibitor BCL2L11, BCL2, BCL2L2 TTR 3460/4885MGLL 3018/4885ENPP2 987/4885
US-20060223852-A1 Pyrazoles GPR119, PDK2, PC TTR 677/4885MGLL 1492/4885ENPP2 2749/4885
US-12509474-B2 Inhibitors of complement factors and uses thereof SSB, UACA, CFH TTR 31/4885MGLL 1431/4885ENPP2 66/4885
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFH, CFB, C5 TTR 49/4885MGLL 416/4885ENPP2 34/4885
US-20250074889-A1 Novel Aminobenzene Derivative Having Cancer Cell Growth Inhibitory Effect, and Preventive or Therapeutic Pharmaceutical Composition Containing Same as Active Ingredient MKI67, CCNB1, ALDH7A1 TTR 4752/4885MGLL 4147/4885ENPP2 4443/4885
US-20250361236-A9 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK TTR 4878/4885MGLL 226/4885ENPP2 439/4885
US-20250257064-A1 TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR BCL2, BAX, BCL2L2 TTR 3062/4885MGLL 2872/4885ENPP2 417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.